And if the shizo trial with 371 does show real positive outcomes that my be all Missling and Anavex needs to keep going with their Sigmar1 stuff because their Sigmar1 stuff does then become real and interesting as a real drug with a future. And the company can survive and have a real possible great future going with 371 even after an EMA failure for 273.
That could well be how this thing plays out. It would be very smart for Missling to do a stock offering to raise money after a successful 371 schizo trial. It would look like he was hedging his bets on the EMA approval but so what? It could also look like there might be hope for the EMA drug too. So it'd be a wash.
Like everything else he's done over the years he'll have everyone totally confused, guessing, but giving him the benefit of all the doubts he also manages to raise! He is a clever one, I'll give him that!
Market Data 
Markets 
